BMS and Anthropic collaborate for Claude implementation

Bristol Myers Squibb (BMS) has entered a strategic agreement with Anthropic to implement its Claude AI platform across its global operations. The collaboration will embed advanced agentic capabilities into BMS’s research, clinical, manufacturing, commercial, and corporate workflows, affecting over 30,000 employees. The focus is on transitioning from basic conversational AI to tools that automate complex tasks, such as data analysis and documentation, while maintaining governance and audit controls. The initiative prioritizes three key areas: engineering and data science, drug advancement, and manufacturing. Claude Code will assist BMS’s engineering and data science teams in enhancing software and AI development, standardizing processes, and unlocking siloed data across systems. Researchers will use advanced reasoning tools to analyze decades of data in oncology, hematology, immunology, and neuroscience, accelerating target identification and reducing documentation timelines for clinical studies and regulatory submissions. In manufacturing and quality, Claude will support root cause investigations, corrective action documentation, and data-driven batch release decisions, improving compliance and expediting patient access to treatments. Commercial and medical affairs teams will leverage the platform to convert field insights into structured intelligence for more effective engagement with healthcare professionals. Anthropic’s head of life sciences, Eric Kauderer-Abrams, highlighted the integration of Claude’s agentic capabilities with BMS’s data repositories, creating a unified intelligence layer. This system can generate clinical study reports, surface relevant scientific context, and trace manufacturing deviations in real time. The partnership follows BMS’s recent $15.2 billion collaboration with Chinese biopharma company Hengrui Pharma, focusing on early-stage oncology, immunology, and hematology assets.